BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BBIO) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for BridgeBio Pharma, Inc. (BBIO), featuring income statements, balance sheets, and cash flow data.
BridgeBio Pharma, Inc. (BBIO) Income Statement & Financial Overview
Explore comprehensive income reports for BridgeBio Pharma, Inc. BBIO, broken down by year and quarter.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $116.63M | $5.88M | $2.73M | $2.17M |
| Cost of Revenue | $605000.00 | $2.08M | $598000.00 | $598000.00 |
| Gross Profit | $116.03M | $3.80M | $2.13M | $1.57M |
| Gross Profit Ratio | $0.99 | $0.65 | $0.78 | $0.72 |
| R&D Expenses | $111.43M | $130.35M | $120.44M | $114.69M |
| SG&A Expenses | $106.36M | $94.78M | $68.82M | $59.52M |
| Operating Expenses | $220.40M | $229.82M | $193.88M | $177.11M |
| Total Costs & Expenses | $221.005M | $231.91M | $194.48M | $177.71M |
| Interest Income | $5.38M | $4.68M | $3.30M | $5.20M |
| Interest Expense | $42.14M | $29.82M | $23.06M | $22.94M |
| Depreciation & Amortization | $1.28M | -$4.71M | $1.54M | $1.57M |
| EBITDA | -$126.18M | -$235.05M | -$139.66M | -$51.03M |
| EBITDA Ratio | -$1.08 | -$39.96 | -$51.12 | -$23.54 |
| Operating Income | -$104.37M | -$226.03M | -$191.75M | -$175.54M |
| Operating Income Ratio | -$0.89 | -$38.43 | -$70.19 | -$80.97 |
| Other Income/Expenses (Net) | -$63.05M | -$40.21M | $27.50M | $100.00M |
| Income Before Tax | -$167.42M | -$266.24M | -$164.25M | -$75.54M |
| Income Before Tax Ratio | -$1.44 | -$45.26 | -$60.12 | -$34.85 |
| Income Tax Expense | $2.19M | $1.15M | $0.00 | $0.00 |
| Net Income | -$167.42M | -$265.05M | -$162.04M | -$73.46M |
| Net Income Ratio | -$1.44 | -$45.06 | -$59.31 | -$33.88 |
| EPS | -$0.88 | -$1.40 | -$0.86 | -$0.39 |
| Diluted EPS | -$0.88 | -$1.40 | -$0.86 | -$0.39 |
| Weighted Avg Shares Outstanding | $190.15M | $189.44M | $188.51M | $187.59M |
| Weighted Avg Shares Outstanding (Diluted) | $190.15M | $189.44M | $188.51M | $187.59M |
Over the past four quarters, BridgeBio Pharma, Inc. demonstrated steady revenue growth, increasing from $2.17M in Q2 2024 to $116.63M in Q1 2025. Operating income reached -$104.37M in Q1 2025, maintaining a consistent -89% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$126.18M, reflecting operational efficiency. Net income rose to -$167.42M, with EPS at -$0.88. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan